Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-873-5 | CAS number: 100-63-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Exposure to phenylhydrazine may cause damage to red blood cells, potentially resulting in anaemia and consequential secondary involvement of other tissues, such as the spleen and liver.
Key value for chemical safety assessment
Additional information
Non-human data:
Data on the oral repeated dose toxicity of phenylhydrazine were available for different species.
Kelly et al. (1969) administered phenylhydrazine hydrochloride to 21 mice by oral gavage once weekly for 8 weeks, at an estimated dose of 85 mg/kg bw/week. There were 10 saline-treated controls. There was 30 % mortality in treated mice compared with none in controls. Further the report described only tumour-related findings.
Haematological changes were reported in four dogs administered 60 mg phenylhydrazine/kg body weight, either as a single dose or as 2, 3, or 10 equal doses on consecutive days (Giffin & Allen, 1928). There was a marked reduction in erythrocyte count that was comparable in magnitude in all dogs at the end of 10 days, but that occurred at a faster rate after a single high dose compared with repeated lower doses.
In another dog study, 60 mg phenylhydrazine/kg body weight was administered daily to three dogs for 5 days (Allen & Giffin, 1928). One animal was moribund at sacrifice on the fifth day and one animal died on the fifth day, although it is not specified that death was treatment related. Full necropsy was performed on only one animal, in which it was found that the blood was brown and did not coagulate readily. Several organs, including the liver and kidneys, were darkly coloured, and several organs contained capillaries engorged with blood. Blood pigment and partially destroyed erythrocytes were found in the spleen. Hepatic cell atrophy was noted, and there was an increase in the iron content of the liver. Similar liver effects were seen in the two other dogs.
Bolton (1935) briefly reported the effect of repeated oral administration of 14 mg phenylhydrazine hydrochloride/ kg body weight to one dog on 4 consecutive days. There was a reduction in erythrocyte count and haemoglobin concentration, whereas white cell count gradually increased. These parameters had returned towards pretreatment values 12 days after the last dose. Pathological findings were reported to be non conclusive.
Overall, the frequency, duration, and level of exposure often varied throughout the studies reported above, so that interpretation of results is difficult. In all studies, phenylhydrazine as phenylhydrazine hydrochloride was administered either by stomach tube or by subcutaneous injection. The authors report that similar findings were obtained regardless of route. There were no control animals. None of the treated animals showed clinical signs of toxicity, and there was no excessive weight loss or gain reported. There were a number of studies available that investigate the effect of short-term repeated parenteral administration of phenylhydrazine (Bodansky, 1923; von Oettingen & Deichmann-Gruebler, 1936; Säterborg, 1974; Ades & Cascarano, 1979; Jain & Hochstein, 1979; Goldstein et al., 1980; Nishida et al., 1982; Dornfest et al.,1986). These studies confirm the ability of phenylhydrazine to damage red blood cells but otherwise do not provide any other information in relation to the toxicity of phenylhydrazine administered by occupationally relevant routes of exposure.
Human data:
No data available.
Justification for classification or non-classification
Based on the results of repeated toxicity testing, phenylhydrazine was not classified according to Regulation 1272/2008/EC (CLP) and Directive 67/548/EC (DSD).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.